Please assess the completion status of the following clinical trial:

Trial Title: Non-Myeloablative Allogeneic HSCT From HLA Matched Related or Unrelated Donors for the Treatment of Low Grade B Cell Malignancies

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Stage II or III non-progressive disease Multiple Myeloma.~* CLL/SLL, and low grade Hodgkin Lymphomas that are in a very good partial response or complete response with non-progressive disease.~* ≤ 70 years old.~* Eligible and willing HLA matched related donor.~* Bilirubin \<2xULN.~* ALT and AST \<3xULN.~* LVEF \> 40%.~* Creatinine Clearance \>40mL/min.~* Pulmonary function DLCO corrected to ≥ 70%.~* Minimum performance score of 70%.~* Platelet count \>130 x103 micro L.~* LDH ≤1.5xULN.~* No proceeding co-morbid condition that significantly increases the risk of severe regimen related toxicity.~* No uncontrolled infections.~Exclusion Criteria:~* Age \>70 years old.~* Performance status \<70%.~* Uncontrolled infections or is HIV positive~* Prior malignancies that are felt to have a \<80% probability of being cured.~* Pregnant, breastfeeding, or refuse to use contraceptive techniques during and for 12 months following transplant.~* Prior Allograft~* History of rapidly growing disease at diagnosis or at any progression or have MDS.~* No eligible and willing HLA matched donor.

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Non Myeloablative Treatment (Type: OTHER): Non-myeloablative Transplant Conditioning Chemotherapy :~Fludarabine - 30 mg/m2/day x 3 days Total Body Irradiation - 200cGy x1 dose Infusion of Stem Cells - On Day 0 pts will received an infusion of HLA matched sibling donor stem cells. Dose is determined by the volume of cells obtained from donor. Minimum dose is 2x10\*6 CD34+ cells per kilogram of recipient weight.

Based on this trial design, predict the completion outcome and termination type (if applicable).